PT  - JOURNAL ARTICLE
AU  - Scott, Jacob G.
AU  - Sedor, Geoffrey
AU  - Ellsworth, Patrick
AU  - Scarborough, Jessica A.
AU  - Ahmed, Kamran
AU  - Oliver, Daniel E.
AU  - Eschrich, Steven A.
AU  - Torres-Roca, Javier F.
AU  - Kattan, Michael W.
TI  - GARD is a pan-cancer predictor of radiation therapy benefit
AID  - 10.1101/2020.12.19.20248484
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.12.19.20248484
4099  - http://medrxiv.org/content/early/2021/05/20/2020.12.19.20248484.short
4100  - http://medrxiv.org/content/early/2021/05/20/2020.12.19.20248484.full
AB  - Background Despite advances in cancer genomics, radiation therapy (RT) is still prescribed based on an empiric one-size-fits-all paradigm. Previously, we proposed a novel algorithm using the genomic adjusted radiation dose (GARD) to personalize RT prescription dose based on the biological effect of a given physical RT dose, calculated using individual tumor genomics. We hypothesize that GARD will reveal interpatient heterogeneity associated with opportunities to improve outcomes compared to physical RT dose alone. To test this hypothesis, and the GARD-based RT dosing paradigm, we performed a pooled pan-cancer analysis in 11 separate clinical cohorts of 1,615 unique patients with 7 different cancer types that represent all available cohorts with the data required to calculate GARD, together with clinical outcome.Methods Using 11 previously-published datasets of cancers including breast, head and neck, non-small cell lung, pancreas, endometrium, melanoma and glioma, we defined two clinical endpoints: (i) time to first recurrence and (ii) overall survival, comprising 1,298 (982 +RT, 316 -RT) and 677 patients (424 +RT, 253 -RT), respectively. We used Cox regression stratified by cohort to test association between GARD and outcome with separate models using RT dose and sham-GARD for comparison. Interaction tests between GARD and treatment (+/- RT) were performed using the Wald statistic.Results Pooled analysis of all available data reveal that GARD as a continuous variable is associated with recurrence (HR = 0.982, CI [0.970, 0.994], p = 0.002) and survival (HR = 0.970, CI [0.953, 0.988], p = 0.001). The interaction test revealed the effect of GARD on survival depends on whether or not that patient received RT (Wald statistic: p=0.011). Physical RT dose and sham-GARD were not significantly associated with either outcome.Conclusions The biologic effect of radiation therapy, as quantified by GARD, is significantly associated with recurrence and survival for those patients treated with radiation: it is predictive of RT benefit; and physical RT dose is not. We propose integration of genomics into radiation dosing decisions, using a GARD-based framework, as the new paradigm for personalizing RT prescription dose.Competing Interest StatementJGS, SAE and JFTR hold IP on RSI, GARD and RxRSI, in addition to equity in Cvergenx, a company which seeks to commercialize these methods.Funding StatementNo funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a retrospective analysis of published data, information on IRB approvals are contained in cited publications.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are published previously in this pooled analysis. The code (and data) are available on github. https://github.com/gsedor/GARD_Meta-Analysis